Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penehyclidine hydrochloride and dexmedetomidine for postoperative cognitive and pulmonary outcomes after cardiopulmonary bypass
ChiCTR2000039610Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of penehyclidine and dexmedetomidine in post-operative cognitive decline (POCD) and postoperative respiratory complications (PRC) (4 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoints: Alveolar-arterial oxygen partial pressure difference, Oxygenation index and 28 more. Started Nov 2020; status: recruiting.
02
Drugs
penehyclidinedexmedetomidine
03
Conditions
post-operative cognitive decline (POCD)postoperative respiratory complications (PRC)
Beyond the preview
Go deeper on ChiCTR2000039610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039610.